Table 3

Association between TSH and markers of disease severity

	Per SD		Per log change in TSH
	95% CI	P value	95% CI	P value
Hazard of mortality
Unadjusted	1.3 (1.0 to 1.8)	0.05	1.9 (1.0 to 3.6)	0.05
Full	1.4 (1.1 to 2.0)	0.02	2.1 (1.0 to 4.2)	0.05
Full+NT-proBNP	1.4 (1.0 to 2.0)	0.08	1.7 (0.8 to 3.6)	0.18
RV basal diameter (cm)
Unadjusted	0.1 (−0.1 to 0.3)	0.18	0.2 (0.0 to 0.4)	0.02
Full	0.1 (−0.1 to 0.3)	0.23	0.2 (0.0 to 0.4)	0.02
Full+NT-proBNP	0.0 (−0.1 to 0.2)	0.82	0.1 (0.0 to 0.3)	0.14
TAPSE (mm)
Unadjusted	−1 (−2 to 0)	0.17	−1 (−2 to 0)	0.07
Full	−1 (−2 to 0)	0.13	−1 (−2 to 0)	0.02
Full+NT-proBNP	−1 (−2 to 1)	0.34	−1 (−2 to 0)	0.09
Walk distance (m)
Unadjusted	−14 (−35 to 6)	0.17	−19 (−43 to 5)	0.11
Full	−12 (−33 to 9)	0.25	−17 (−41 to 7)	0.16
Full+NT-proBNP	−1 (−20 to 18)	0.92	−7 (−29 to 15)	0.55
NYHA Functional Class
Unadjusted	1.3 (0.9 to 2.0)	0.21	1.3 (0.8 to 2.2)	0.27
Full	1.4 (0.9 to 2.2)	0.19	1.4 (0.8 to 2.5)	0.19
Full+NT-proBNP	1.2 (0.7 to 2.0)	0.44	1.2 (0.7 to 2.3)	0.51

Full model accounted for differences in age, sex at birth and aetiology of pulmonary hypertension.
Hazard of mortality was estimated using Cox proportional hazards, RV basal diameter/TAPSE/walk distance were estimated using linear regression, the odds of NYHA Functional Class of III/IV relative to I/II were estimated using logistic regression.
Coefficients represent relationships for an SD difference in TSH.
Value in bold indicates statistically significant results.
NT-proBNP, N-terminal-pro hormone brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TSH, thyroid-stimulating hormone.